Background It is uncertain whether bridging anticoagulation is necessary for patients with
atrial fibrillation who need an interruption in warfarin treatment for an elective operation or …

Background Four direct oral anticoagulants (DOACs) have been brought to market for the
treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces …

Background Currently there is lack of head-to-head comparisons between different Non-
Vitamin K Antagonist Oral Anticoagulants (NOACs), especially in more risky subgroups, as …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background Direct oral anticoagulants (DOAC s) are noninferior to warfarin for stroke
prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and …

Background and Purpose—Prolonged ambulatory ECG monitoring after cryptogenic stroke
improves detection of covert atrial fibrillation, but its long-term cost-effectiveness is uncertain …

Introduction: This review attempts to summarise what is known about Drug-drug interactions
(DDIs) of the new oral anticoagulants (NOACs) in elderly patients. The literature was …

Aims The aim of the present study was to assess the effect of policy interventions–ie
reimbursement decisions, guidelines and regional recommendations–on the prescribing of …

Objective To assess the cost-effectiveness of pharmacogenomics (PGx)-based warfarin (ie,
warfarin dosing following genetic testing), apixaban, and rivaroxaban oral anticoagulation …

Guidelines advise performing a computed tomography head scan for all anticoagulated
head injured patients, but the risk of intracranial haemorrhage (ICH) after a minor head …